Preparation and application background and overview of 2-methylpyridine-3-boronic acid
2-Methylpyridine-3-boronic acid is an organic intermediate that can be prepared in one step from 3-bromo-2-methylpyridine and triisopropyl borate. 2-Methylpyridine-3-boronic acid can be used to participate in the Suzuki reaction.
Preparation and application of 2-methylpyridine-3-boronic acid
To 3-bromo-2-methylpyridine (4.00 g, 23 mmol) and triisopropyl borate (6.40 mL, 28 mmol) in 50 mL of 4/1 toluene/THF ( 4/1, 50 mL) solution was added dropwise butyllithium (17 mL, 28 mmol). The mixture was allowed to heat to -70°C and then to 20°C over 30 minutes. HCl (2M) was added to bring the solution to pH 1. Water (20 mL) was then added and the mixture was extracted with toluene. The aqueous layer was neutralized with 1M NaOH and extracted with dichloromethane. The aqueous layer was concentrated to dryness and the white solid was washed with dichloromethane. The combined organic layers were dried over sodium sulfate, filtered and concentrated to give 2.10 g of 2-methylpyridine-3-boronic acid as a yellow oil. ES+=138.2(M+H).
Preparation and application of 2-methylpyridine-3-boronic acid
Preparation and application report of 2-methylpyridine-3-boronic acid 1.
2-Methylpyridine-3-boronic acid can be used to prepare compounds that inhibit or modulate the interaction of WDR5 with chromatin, homologous transcription and other regulatory factors, including, for example, histone methyl transfer enzyme MLL1 and may provide treatments for cancers associated with such interactions (e.g., MLL1 lithium carbonate-WDR5 interaction).
Methoxypyridine
Preparation and application report 2 of 2-methylpyridine-3-boronic acid,
2-Methylpyridine-3-boronic acid may also be used to prepare compounds that serve as inhibitors of phosphodiesterase type 10A and are suitable for the treatment or control of medical conditions selected from neurological disorders and psychiatric disorders. .
References
[1] From PCT Int. Appl., 2006094187, 08 Sep 2006
[2] From U.S. Pat. Appl. Publ., 20200102288, 02 Apr 2020
[3] [Invented in China] CN201380048224.3 New inhibitor compound of phosphodiesterase type 10A
